September 19, 2019
Clinical Articles
NTRK fusions, although rare, have been identified as an important driver of oncogenic activity in a variety of cancer types. Advances in the understanding of TRK family biology, coupled with the growing recognition of TRK alterations as drivers of oncogenesis across tumor types, has fueled interest in the development of small molecule inhibitors of TRK.
September 19, 2019
Clinical Articles
Alexander Drilon, MD, speaks to the significance of TRK gene fusions and treatments for targeting these fusions in patients with cancer.